Wolf Haldenstein says Aardvark investors can seek lead-plaintiff role in securities suit
The law firm says a securities class action was filed in federal court in San Diego over Aardvark Therapeutics shares, with a lead-plaintiff deadline of Oct. 13, 2026.
Wolf Haldenstein Adler Freeman & Herz LLP says a securities class action has been filed in the United States District Court for the Southern District of California over shares of Aardvark Therapeutics Inc. (NASDAQ: AARD).
The firm said the case covers people or entities that purchased or otherwise acquired Aardvark shares, and it set an Oct. 13, 2026, deadline to seek appointment as lead plaintiff.
Wolf Haldenstein said the complaint centers on Aardvark's February disclosure and the company’s later share-price decline. The law firm said the complaint alleges defendants failed to disclose certain information to investors. The notice does not prove the claims, and the allegations have not been tested in court.
According to the press release, the alleged truth began to emerge on Feb. 27, 2026, when Aardvark said it was voluntarily pausing its Phase 3 Hunger Elimination or Reduction Objective, or HERO, trial. The company said that decision followed reversible cardiac observations at above-target therapeutic doses found during routine safety monitoring in a healthy volunteer study.
The release also said Aardvark paused ongoing enrollment and dosing in the HERO trial while it conducted a comprehensive review of the data to inform next steps.
Wolf Haldenstein said Aardvark shares fell $7.02, or 56.2%, to close at $5.47 on March 2, 2026, after the February announcement. The firm identified its Sept. 2, 2026, press release as the basis for the lead-plaintiff notice.
The notice says investors who bought or otherwise acquired Aardvark shares during the class period and suffered losses may be eligible to participate. It also says there is no cost or obligation to speak with an attorney.
The case remains pending in federal court in Southern California, and the lead-plaintiff deadline named in the notice is Oct. 13, 2026.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.